发表论文
1 Yin, L.; Hu, Q.; Emmerich, J.; Lo, M. M.; Metzger, E.; Ali, A.; Hartmann, R. W. Novel pyridyl- or isoquinolinyl- substituted indolines and indoles as potent and selective aldosterone synthase inhibitors. J. Med. Chem. 2014, 57, 5179–5189.
2 Yin, L.; Hu, Q.* CYP17 inhibitors — abiraterone, C17,20-lyase inhibitors and multi-targeting agents. Nat. Rev. Urol. 2014, 11, 32-42.
3 Yin, L.; Hu, Q.* Chimera induced protein degradation: PROTACs and beyond. Euro. J. Med. Chem. 2020, 206, 112494
4 Zhu, H.; Liu, M.; Li, H.; Guan, T.; Zhang, Q.; Chen, Y.; Liu, Y.; Hartmann, R. R.; Yin, L.;* Hu, Q.* Design, synthesis and biological evaluation of pyridyl substituted benzoxazepinones as potent and selective inhibitors of aldosterone synthase. Chin. Chem. Lett. 2021, 32, 2327-2332.
5 Yin, L.;* Xue, Y.; Shang, Q.; Zhu, H.; Liu, M.; Liu, Y.; Hu, Q.* Pharmaceutical inhibition of neddylation as promising treatments for various cancers. Curr. Top. Med. Chem. 2019, 19, 1059-1069.
6 Yin, L.; Hu, Q.; Hartmann, R. W. Tetrahydropyrroloquinolinone type dual inhibitors of aromatase / aldosterone synthase as a novel strategy for breast cancer patients with elevated cardiovascular risks. J. Med. Chem. 2013, 56, 460–470.
7 Yin, L.; Lucas, S.; Maurer, F.; Kazmaier, U.; Hu, Q.;* Hartmann, R. W.* Novel imidazol-1-ylmethyl substituted 1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-ones as potent and selective CYP11B1 inhibitors for the treatment of Cushing’s syndrome. J. Med. Chem. 2012, 55, 6629–6633.
8 Yin, L.; Hu, Q.* Drug discovery for breast cancer and coinstantaneous cardiovascular disease: What is the future? Future Med. Chem. 2013, 5, 359–362.
9 Ma, L.; Yin, L.;* Hu, Q.* Therapeutic compounds for Cushing's syndrome: a patent review (2012-2016). Expert Opin. Ther. Pat. 2016, 26, 1307–1323.
10 Hu, Q.; Yin, L.; Ali, A.; Cooke, A. J.; Bennett, J.; Ratcliffe, P.; Lo, M. M.; Metzger, E.; Hoyt, S.; Hartmann, R. W. Novel pyridyl substituted 4,5-dihydro-[1,2,4]triazolo[4,3-a]quinolines as potent and selective aldosterone synthase inhibitors with improved in vitro metabolic stability. J. Med. Chem. 2015, 58, 2530–2537.
11 Hu, Q.; Yin, L.; Hartmann, R. W. Aldosterone synthase inhibitors as promising treatments for mineralocorticoid dependent cardiovascular and renal diseases. J. Med. Chem. 2014, 57, 5011–5022.
12 Hu, Q.; Yin, L.; Hartmann, R. W.* Selective dual inhibitors of CYP19 and CYP11B2: targeting cardiovascular diseases hiding in the shadow of breast cancer. J. Med. Chem. 2012, 55, 7080–7089.
